Patents by Inventor Yelena Kovtun

Yelena Kovtun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11046762
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: June 29, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Publication number: 20210147560
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Application
    Filed: October 22, 2020
    Publication date: May 20, 2021
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Patent number: 10919969
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: February 16, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Patent number: 10875925
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: December 29, 2020
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Publication number: 20200239580
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Application
    Filed: January 31, 2020
    Publication date: July 30, 2020
    Inventors: YELENA KOVTUN, DANIEL J. TAVARES, LINGYUN RUI, THOMAS CHITTENDEN
  • Publication number: 20200148764
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Application
    Filed: October 14, 2019
    Publication date: May 14, 2020
    Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Patent number: 10494431
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: December 3, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Patent number: 10442865
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the a chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: October 15, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Publication number: 20180355047
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the a chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Application
    Filed: April 19, 2018
    Publication date: December 13, 2018
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Publication number: 20180291100
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Application
    Filed: March 5, 2018
    Publication date: October 11, 2018
    Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Patent number: 10077313
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: September 18, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel Tavares, Lingyun Rui, Thomas Chittenden
  • Publication number: 20180079819
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Application
    Filed: August 3, 2017
    Publication date: March 22, 2018
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Publication number: 20170157264
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Application
    Filed: October 14, 2016
    Publication date: June 8, 2017
    Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Publication number: 20170080102
    Abstract: The invention features methods for characterizing and treating acute myeloid leukemia (AML) (e.g., newly diagnosed, relapsed, and refractory AML) in a subject using immunoconjugates of the invention. In one aspect, the invention generally features a method of treating acute myeloid leukemia in a subject (e.g., a human), the method involving administering an effective amount of an immunoconjugate to a pre-selected subject, where the immunoconjugate contains a humanized or chimeric antibody or fragment conjugated to a cytotoxic benzodiazepine dimer compound via a cleavable disulfide linker.
    Type: Application
    Filed: May 19, 2015
    Publication date: March 23, 2017
    Inventors: Kathleen R. Whiteman, Paul Noordhuis, Yelena Kovtun, Robert J. Lutz, Gerrit Jan Schuurhuis, Russell Marlin Walker
  • Publication number: 20170029514
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Application
    Filed: June 28, 2016
    Publication date: February 2, 2017
    Inventors: Yelena Kovtun, Daniel Tavares, Lingyun Rui, Thomas Chittenden
  • Patent number: 9498541
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: November 22, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Publication number: 20160114052
    Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.
    Type: Application
    Filed: August 25, 2015
    Publication date: April 28, 2016
    Applicant: IMMUNOGEN, INC.
    Inventors: Rajeeva Singh, Yelena Kovtun, Sharon D. Wilhelm, Ravi V.J. Chari
  • Publication number: 20150352223
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Application
    Filed: May 15, 2015
    Publication date: December 10, 2015
    Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Patent number: 9150649
    Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: October 6, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Rajeeva Singh, Yelena Kovtun, Sharon D. Wilhelm, Ravi V. J. Chari
  • Patent number: 9061995
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: June 23, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison